Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.47 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.46 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.45 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.44 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.42 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.42 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.41 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736064 | 0.99 | ROCK2 (0.47) | ROCK2SLC6A4PARP14ITGB3ITGA2B | |
| SCHEMBL28284087 | 0.89 | PARP14 (0.51) | PARP14OPRM1OPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6393378 | 0.86 | OPRM1 (0.55) | ROCK2SLC6A4PARP14ITGB3ITGA2B | |
| SCHEMBL4974021 | 0.85 | OPRM1 (0.56) | ROCK2SLC6A4PARP14ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL1532745 | 0.83 | MAOB (0.56) | ITGB3ITGA2BCHEK2ACP1MAOB | |
| SCHEMBL12736067 | 0.82 | ROCK2 (0.53) | ROCK2ITGB3ITGA2BMAP1LC3BMAP1LC3A | |
| SCHEMBL12736089 | 0.82 | ROCK2 (0.45) | ROCK2ITGB3ITGA2BMAP1LC3BMAP1LC3A | |
| SCHEMBL12735893 | 0.81 | MAOB (0.58) | ITGB3ITGA2BCHEK2ACP1MAOB | |
| Hydrochloric Acid SCHEMBL1532738 | 0.81 | PARP14 (0.44) | ROCK2PARP14ITGB3ITGA2BACP1 | |
| SCHEMBL12736091 | 0.80 | PARP1 (0.48) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| CN-101160287-B | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative | ASTELLAS PHARMA INC | 2011-08-03 | — | — | CN | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| CN-101160287-A | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative | ASTELLAS PHARMA INC (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | ROCK2 4127/4885SLC6A4 713/4885ITGB3 3765/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | ROCK2 3621/4885SLC6A4 530/4885ITGB3 3443/4885 |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR1 | ROCK2 3648/4885SLC6A4 548/4885ITGB3 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.